A letter to Health Affairs, citing a French initiative on lung cancer molecular profiling for deciding therapy (see separate blog post). The author of the letter points out:

“…specialty pharmaceuticals—or, more broadly, personalized medicine—are touted as the future of medical care because they make more treatments more effective, [but] there are reservations about the value that they offer society as a whole, compared to certain population groups.”

“…we know little about the intended and unintended health, economic, and social impacts of personalized medicine!

Pricivel M. Carrera : http://content.healthaffairs.org/content/34/1/188.3.full?rss=1